Tapentadol Market: Global Industry Trend Analysis 2031


The tapentadol market has been estimated to expand at a CAGR of 6.1% in the upcoming years from 2020 to 2030.

Neuropathic pain is generally caused due to lesions to or dysfunction of the peripheral or central nervous system. Further, it is basically chronic in nature along with complex pathophysiology. Tapentadol (NUCYNTA ER) is used at an increased rate to treat neuropathic pain. These factors are predicted to bolster growth opportunities in the tapentadol market in the near future.

Tapentadol is a dual mode analgesic that performs the actions of being a norepinephrine reuptake inhibitor as well as a mu-opioid receptor antagonist. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain.

Some of the key players operating in the global tapentadol market so far, have been Johnson Johnson Pharmaceutical Research Development, L.L.C., IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Cadila Pharmaceuticals Ltd., Tirupati Medicare Ltd, and Manus Aktteva Biopharma LLP.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in today’s supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

 


Rohit Bhisey
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Visit Site: https://www.tmrresearch.com/